Trial Profile
A Double-blind, Randomized, Two-period Crossover Study Evaluating the Effects of Tasimelteon vs. Placebo on Sleep Disturbances of Individuals With Smith-Magenis Syndrome (SMS)
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 21 Nov 2022
Price :
$35
*
At a glance
- Drugs Tasimelteon (Primary)
- Indications Circadian rhythm sleep disorders
- Focus Proof of concept; Therapeutic Use
- Sponsors Vanda Pharmaceuticals
- 15 Nov 2022 Status changed from recruiting to completed.
- 10 Dec 2018 Primary endpoint (daily diary sleep quality (DDSQ) (50% worst sleep quality)) has been met, according to a Vanda Pharmaceuticals media release.
- 10 Dec 2018 Results presented in the Vanda Pharmaceuticals media release.